Basic Information
RNALocate ID: | RLID-D:11000135 |
RNA Symbol: | hsa-miR-335-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-335-5p |
RNA ID: | miRBase:MIMAT0000765 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
Tissue/Cell Line: | Blood|Breast milk|Endothelial cells|Seminal fluid |
Database: | EVmiRNA |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01002092 | Nucleus | Neural progenitor cells | 21363885 |
RLID:11002662 | Exosome | Serum | 18589210 |
RLID:11002663 | Exosome | Saliva | 19627513 |
RLID:11002664 | Exosome | B cell line (Raji)|Jurkat-derived T cell line (J77cl20)|Primary dendritic cells | 21505438 |
RLID:11002665 | Exosome | Renal cancer cells | 21670082 |
RLID:11002666 | Exosome | Breast milk | 22211110 |
RLID:11002667 | Exosome | Brain tissue | 23382797 |
RLID:11002668 | Exosome | Plasma | 23663360 |
RLID:11002669 | Exosome | Serum | 25349172 |
RLID:11002670 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000442 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-335-5p | Splenic marginal zone lymphoma | MNDR-E-MI-40952 |
MNDR | hsa-miR-335-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-40953 |
MNDR | hsa-miR-335-5p | Medulloblastoma | MNDR-E-MI-40954 |
MNDR | hsa-miR-335-5p | Ovarian clear cell carcinoma | MNDR-E-MI-40955 |
MNDR | hsa-miR-335-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-40956 |
MNDR | hsa-miR-335-5p | Lymphoma non-hodgkin | MNDR-E-MI-40957 |
MNDR | hsa-miR-335-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-40958 |
MNDR | hsa-miR-335-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-40959 |
MNDR | hsa-miR-335-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-40960 |
MNDR | hsa-miR-335-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-40961 |
MNDR | hsa-miR-335-5p | Her2-receptor positive breast cancer | MNDR-E-MI-40962 |
MNDR | hsa-miR-335-5p | Breast cancer luminal | MNDR-E-MI-40963 |
MNDR | hsa-miR-335-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-40964 |
MNDR | hsa-miR-335-5p | Dermatomyositis | MNDR-E-MI-40965 |
MNDR | hsa-miR-335-5p | Prostate cancer | MNDR-E-MI-40966 |
MNDR | hsa-miR-335-5p | Gastric cancer | MNDR-E-MI-40967 |
MNDR | hsa-mir-335-5p | Gastric cancer | MNDR-E-MI-40968 |
MNDR | hsa-miR-335-5p | Alzheimer disease | MNDR-E-MI-40969 |
MNDR | hsa-miR-335-5p | Bladder cancer | MNDR-E-MI-40970 |
MNDR | hsa-miR-335-5p | Sarcoma | MNDR-E-MI-40971 |
MNDR | hsa-miR-335-5p | Dysautonomia familial | MNDR-E-MI-40972 |
MNDR | hsa-miR-335-5p | Myotonic dystrophy | MNDR-E-MI-40973 |
MNDR | hsa-miR-335-5p | Duchenne muscular dystrophy | MNDR-E-MI-40974 |
MNDR | hsa-miR-335-5p | Facioscapulohumeral muscular dystrophy | MNDR-E-MI-40975 |
MNDR | hsa-miR-335-5p | Leukemia | MNDR-E-MI-40976 |
MNDR | hsa-miR-335-5p | Huntington disease | MNDR-E-MI-40977 |
MNDR | hsa-miR-335-5p | Cardiovascular disease | MNDR-E-MI-40978 |
MNDR | hsa-miR-335-5p | Uterine fibroid | MNDR-E-MI-40979 |
MNDR | hsa-miR-335-5p | Lung cancer | MNDR-E-MI-40980 |
MNDR | hsa-miR-335-5p | Parkinson disease | MNDR-E-MI-40981 |
MNDR | hsa-miR-335-5p | Basal-like breast cancer | MNDR-E-MI-40982 |
MNDR | hsa-miR-335-5p | Thyroid cancer | MNDR-E-MI-40983 |
MNDR | hsa-miR-335-5p | Pituitary neoplasms | MNDR-E-MI-40984 |
MNDR | hsa-miR-335-5p | Pancreatic cancer | MNDR-E-MI-40985 |
MNDR | hsa-miR-335-5p | Rectum adenocarcinoma | MNDR-E-MI-40986 |
MNDR | hsa-miR-335-5p | Nephroblastoma | MNDR-E-MI-40987 |
MNDR | hsa-miR-335-5p | Colon cancer | MNDR-E-MI-40988 |
MNDR | hsa-miR-335-5p | Colon adenocarcinoma | MNDR-E-MI-40989 |
MNDR | hsa-miR-335-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-40990 |
MNDR | hsa-miR-335-5p | Familial ovarian cancer | MNDR-E-MI-40991 |
MNDR | hsa-miR-335-5p | Prostate adenocarcinoma | MNDR-E-MI-40992 |
MNDR | hsa-miR-335-5p | Carcinoma ductal breast | MNDR-E-MI-40993 |
MNDR | hsa-miR-335-5p | Invasive ductal carcinoma | MNDR-E-MI-40994 |
MNDR | hsa-miR-335-5p | Glioblastoma | MNDR-E-MI-40995 |
MNDR | hsa-miR-335-5p | Malignant astrocytoma | MNDR-E-MI-40996 |
MNDR | hsa-miR-335-5p | Glioma | MNDR-E-MI-40997 |
MNDR | hsa-miR-335-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-40998 |
MNDR | hsa-miR-335-5p | Nemaline myopathy | MNDR-E-MI-40999 |
MNDR | hsa-miR-335-5p | Neurilemmoma | MNDR-E-MI-41000 |
MNDR | hsa-miR-335-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-41001 |
MNDR | hsa-miR-335-5p | Temporal lobe epilepsy | MNDR-E-MI-41002 |
MNDR | hsa-miR-335-5p | Osteosarcoma | MNDR-E-MI-41003 |
MNDR | hsa-miR-335-5p | Liposarcoma | MNDR-E-MI-41004 |
MNDR | hsa-miR-335-5p | Breast carcinoma | MNDR-E-MI-41005 |
MNDR | hsa-miR-335-5p | Meningioma | MNDR-E-MI-41006 |
MNDR | hsa-miR-335-5p | Pituitary adenoma | MNDR-E-MI-41007 |
MNDR | hsa-miR-335-5p | Lung squamous cell carcinoma | MNDR-E-MI-41008 |
MNDR | hsa-miR-335-5p | Lung adenocarcinoma | MNDR-E-MI-41009 |
MNDR | hsa-miR-335-5p | Thyroid carcinoma | MNDR-E-MI-41010 |
MNDR | hsa-miR-335-5p | Pancreatic adenocarcinoma | MNDR-E-MI-41011 |
MNDR | hsa-miR-335-5p | Carcinoma renal cell | MNDR-E-MI-41012 |
MNDR | hsa-miR-335-5p | Papillary renal cell carcinoma | MNDR-E-MI-41013 |
MNDR | hsa-miR-335-5p | Clear cell renal cell carcinoma | MNDR-E-MI-41014 |
MNDR | hsa-miR-335-5p | Chromophobe renal cell carcinoma | MNDR-E-MI-41015 |
MNDR | hsa-miR-335-5p | Cholangiocarcinoma | MNDR-E-MI-41016 |
MNDR | hsa-miR-335-5p | Esophageal cancer | MNDR-E-MI-41017 |
MNDR | hsa-miR-335-5p | HIV | MNDR-E-MI-41018 |
MNDR | hsa-miR-335-5p | Oncocytoma | MNDR-E-MI-41019 |
MNDR | hsa-miR-335-5p | Lung small cell carcinoma | MNDR-E-MI-41020 |
MNDR | hsa-miR-335-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-41021 |
MNDR | hsa-miR-335-5p | Testicular germ cell cancer | MNDR-E-MI-41022 |
MNDR | hsa-miR-335-5p | T acute lymphoblastic leukemia | MNDR-E-MI-41023 |
MNDR | hsa-miR-335-5p | Acute t cell leukemia | MNDR-E-MI-41024 |
MNDR | hsa-miR-335-5p | Fibromyalgia | MNDR-E-MI-41025 |
MNDR | hsa-miR-335-5p | Breast invasive carcinoma | MNDR-E-MI-41026 |
MNDR | hsa-miR-335-5p | Hepatocellular carcinoma | MNDR-E-MI-41027 |
MNDR | hsa-miR-335-5p | Familiar ovarian carcinoma | MNDR-E-MI-41028 |
MNDR | hsa-miR-335-5p | B-cell lymphoma | MNDR-E-MI-41029 |
MNDR | hsa-miR-335-5p | Rheumatoid arthritis | MNDR-E-MI-41030 |
MNDR | hsa-miR-335-5p | T-cell leukemia | MNDR-E-MI-41031 |
MNDR | hsa-miR-335-5p | Neuroblastoma | MNDR-E-MI-41032 |
MNDR | hsa-miR-335-5p | Barrett's adenocarcinoma | MNDR-E-MI-41033 |
MNDR | hsa-miR-335-5p | Hodgkin lymphoma | MNDR-E-MI-41034 |
MNDR | hsa-miR-335-5p | Burkitt lymphoma | MNDR-E-MI-41035 |
MNDR | hsa-miR-335-5p | Myeloid leukemia | MNDR-E-MI-41036 |
MNDR | hsa-miR-335-5p | Neuromyelitis optica | MNDR-E-MI-41037 |
MNDR | hsa-miR-335-5p | Acute myeloid leukemia | MNDR-E-MI-41038 |
MNDR | hsa-miR-335-5p | Colorectal cancer | MNDR-E-MI-41039 |
MNDR | hsa-miR-335-5p | Nasopharynx carcinoma | MNDR-E-MI-41040 |
MNDR | hsa-miR-335-5p | Ependymoma | MNDR-E-MI-41041 |
MNDR | hsa-miR-335-5p | Nasopharyngeal cancer | MNDR-E-MI-41042 |
MNDR | hsa-miR-335-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-41043 |
MNDR | hsa-miR-335-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-41044 |
MNDR | hsa-miR-335-5p | Sarcopenia | MNDR-E-MI-41045 |
MNDR | hsa-miR-335-5p | Stroke lacunar | MNDR-E-MI-41046 |
MNDR | hsa-miR-335-5p | Non-alcoholic fatty liver disease | MNDR-E-MI-41047 |
MNDR | hsa-miR-335-5p | Barrett's carcinogenesis | MNDR-E-MI-41048 |
MNDR | hsa-miR-335-5p | Breast cancer her3+ negative | MNDR-E-MI-41049 |
MNDR | hsa-miR-335-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-41050 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ARPC5L | Homo sapiens | RR00130405 |
TOP